Bayer HOT Aspirin Study Interpretation Gets Lukewarm FDA Feedback
This article was originally published in The Tan Sheet
Executive Summary
FDA's review of the studies used by Bayer to support an aspirin indication for primary prevention of myocardial infarction suggests "a substantially weaker result than is published," according to the agency
You may also be interested in...
Non-Fatal MI Prevention Indication For Aspirin May Cause Bayer Less Pain
Bayer may have a better shot of gaining FDA approval of expanded professional labeling for aspirin by pursuing an indication for prevention of non-fatal myocardial infarction. The firm got a negative advisory committee vote for prevention of all MIs at a Dec. 8 meeting
Non-Fatal MI Prevention Indication For Aspirin May Cause Bayer Less Pain
Bayer may have a better shot of gaining FDA approval of expanded professional labeling for aspirin by pursuing an indication for prevention of non-fatal myocardial infarction. The firm got a negative advisory committee vote for prevention of all MIs at a Dec. 8 meeting
Non-Fatal MI Prevention Indication For Aspirin May Cause Bayer Less Pain
Bayer may have a better shot of gaining FDA approval of expanded professional labeling for aspirin by pursuing an indication for prevention of non-fatal myocardial infarction. The firm got a negative advisory committee vote for prevention of all MIs at a Dec. 8 meeting